Clinical Trial Update: Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study to assess the distribution, metabolism, and excretion of a single-dose intravenous [14C]AZD6765 in Major Depressive Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• AZD6765 (lanicemine)

Snippet

Sponsor: AstraZeneca | Conditions: Major Depressive Disorder | Phase 1 | Status: COMPLETED